Although the sample size of this study was small, this is the first report of QOL and Treg analyses in advanced HER2-positive breast cancer patients who received PTE therapy, and the results showed that PTE therapy maintained the QOL of patients with advanced HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.